German chemicals giant Evonik has announced a strategic restructuring of its healthcare and adhesives divisions to focus on high-growth markets. The company plans to double down on lipids for mRNA therapies and drug delivery systems as part of its healthcare strategy.

⚠ Challenges faced: 🔹 Declining demand for certain chemical products 🔹 Market shifts towards biotech-driven solutions 🔹 Need for greater R&D investments in healthcare

🔗 Read more: Reuters